β-defensin 14 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of β-defensin 14, a member of the defensin family of small, cysteine-rich antimicrobial peptides. β-defensin 14 plays an essential role in the innate immune system, contributing to the defense against pathogens such as bacteria, fungi, and viruses by disrupting their cell membranes. This peptide is known for its ability to bind to microbial cell surfaces, leading to membrane destabilization and the destruction of pathogens. Inhibitors of β-defensin 14 aim to block its antimicrobial activity, potentially affecting the peptide's ability to bind to microbial membranes or interact with specific components of the immune response.
The development of β-defensin 14 inhibitors involves a detailed understanding of the peptide's structure, particularly its β-sheet-rich conformation stabilized by disulfide bridges, which is essential for its function in binding to microbial surfaces. These inhibitors are designed to interact with key regions of the peptide, such as its positively charged surface or hydrophobic regions, which are critical for membrane binding and antimicrobial activity. Structural biology techniques, including molecular modeling and X-ray crystallography, are commonly employed to identify these critical regions and to design inhibitors that specifically bind to them, preventing β-defensin 14 from carrying out its membrane-disrupting functions. Achieving high specificity is crucial in this process, as β-defensin 14 shares structural and functional similarities with other members of the defensin family. These inhibitors are valuable tools for studying the detailed mechanisms of host-microbe interactions, shedding light on the complex dynamics of innate immune responses and the role of defensins in protecting against microbial invaders.
Siehe auch...
Artikel 1 von 10 von insgesamt 12
Anzeigen:
| Produkt | CAS # | Katalog # | Menge | Preis | Referenzen | Bewertung |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | ¥1715.00 ¥5404.00 ¥7130.00 ¥13798.00 ¥24053.00 | 33 | |
Trichostatin A hemmt Histon-Deacetylasen, was möglicherweise die Expression von RIM-BP3B durch eine Veränderung der Chromatinstruktur reduziert. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | ¥3159.00 | 4 | |
Dieser DNA-Methyltransferase-Inhibitor kann die RIM-BP3B-Expression durch Beeinflussung der Genmethylierungsmuster verringern. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | ¥835.00 ¥2742.00 ¥8247.00 ¥29017.00 ¥246489.00 | 53 | |
Actinomycin D bindet an die DNA und hemmt die Wirkung der RNA-Polymerase, wodurch die mRNA-Synthese von RIM-BP3B möglicherweise reduziert wird. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | ¥3035.00 ¥11846.00 | 26 | |
α-Amanitin hemmt die RNA-Polymerase II, was zu einer verringerten Transkription von RIM-BP3B führen könnte. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | ¥711.00 ¥1783.00 ¥3678.00 | 233 | |
Sirolimus hemmt mTOR, was die Expression von RIM-BP3B durch Beeinträchtigung der Proteinsynthesewege herunterregulieren kann. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | ¥463.00 ¥948.00 ¥3103.00 | 127 | |
Cycloheximid hemmt die eukaryotische Proteinsynthese und vermindert möglicherweise die Produktion von RIM-BP3B. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | ¥778.00 | 2 | |
Chloroquin kann Lysosomen alkalisieren und dadurch möglicherweise die Abbauwege der RIM-BP3B mRNA stören. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | ¥1388.00 ¥4513.00 | 148 | |
LY294002 ist ein PI3K-Inhibitor, der durch die Beeinflussung nachgeschalteter Signale zu einer verminderten Expression von RIM-BP3B führen könnte. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | ¥621.00 | 6 | |
Mithramycin A bindet an die DNA und verringert möglicherweise die RIM-BP3B-Expression durch Hemmung der RNA-Synthese. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | ¥790.00 ¥2426.00 | 26 | |
Es hemmt die Glykolyse, wodurch möglicherweise die Energie für die RIM-BP3B-Expression und andere zelluläre Prozesse reduziert wird. | ||||||